Detalhe da pesquisa
1.
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02).
Cancer Discov
; 10(8): 1158-1173, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32439653